dextroamphetamine immediate release / Generic mfg. - LARVOL DELTA

Do Stimulants Promote Arrhythmic Risk: Insights From a Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model. (PubMed, J Arrhythm) - "Atrial and ventricular hiPSC-CMs were plated on a multielectrode array (MEA) platform and exposed to clinically relevant plasma concentrations of methylphenidate, dextroamphetamine, atomoxetine, caffeine, or the β-agonist isoproterenol. The preservation of CV suggests that these compounds are unlikely to alter myocardial conduction at therapeutic doses. The observed effects on BR and FPDc warrant further mechanistic studies to understand how these changes may contribute to arrhythmia risk in susceptible populations."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Psychiatry

A Rare Case of Therapeutic Amphetamine-Dextroamphetamine-Induced Ischemic Colitis in a Middle-Aged Woman Without Traditional Vascular Risk Factors (ACG 2026) - "Amphetamine-dextroamphetamine (Adderall), commonly prescribed for ADHD, has rarely been implicated...Medications included amphetamine-dextroamphetamine ER 15 mg daily, semaglutide, escitalopram, clonidine, and rosuvastatin...The medication was discontinued, and the patient improved with IV fluids, ceftriaxone, and metronidazole...As prescription stimulant use increases, clinicians should remain aware of this rare adverse effect, as early recognition and discontinuation of the offending agent may prevent recurrent ischemia and complications. Figure: Ischemic-type changes characterized by hyalinization of the lamina propria (highlighted by the Sirius red stain), surface erosion, withering crypts and focal pseudomembranous exudates Figure: Segmental mucosal friability and ulcerative ischemic injury involving the sigmoid colon"

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Cognitive Disorders • Endometriosis • Gastroenterology • Gastrointestinal Disorder • Gynecology • Hematological Disorders • Immunology • Inflammation • Women's Health

Acute lipopolysaccharide (LPS) treatment in male mice exacerbates dextroamphetamine-induced hyperlocomotion without detectable changes in nucleus accumbens dopaminergic activity. (PubMed, Brain Behav Immun) - "We found that dysregulation of mRNA levels of all three measured kynurenine pathway enzymes (TDO2, KAT II, KMO) was present in the LPS group following behavioural testing. Taken together, our findings suggest that while inflammation augments psychosis-relevant mouse behaviour, dopamine may not to be the key driver."

Journal • Preclinical • CNS Disorders • Inflammation • Mental Retardation • Psychiatry • Schizophrenia • FOS • IL1B • TDO2

Study on the toxicokinetics and in vivo distribution of benzylpiperazine (BZP) and 1-(3-(trifluoromethyl)phenyl)piperazine (TFMPP) after single and combined administration in Wistar rats. (PubMed, Drug Chem Toxicol) - "Their combined use produces cardiovascular stimulation (hypertension and tachycardia) comparable to dextroamphetamine, yet data on their toxicokinetics and tissue distribution are scarce...For TFMPP, the distribution pattern under combined administration was the same as that of BZP; however, when administered alone, its concentration in the brain was higher than that in the spleen. These findings indicate that co‑exposure to BZP and TFMPP can modify toxicokinetic behavior and tissue distribution, suggesting distinct poisoning dynamics from exposure to either compound alone."

Journal • Preclinical • Cardiovascular • Hypertension

Dexamphetamine-induced striatal hyperdopaminergia attenuates reward-related neural activation: A11C-PHNO PET-fMRI study. (PubMed, Biol Psychiatry) - "These findings support a mechanism by which elevated dopamine may impair motivational coding by reducing amplification of goal-relevant information, with potential relevance to negative symptoms such as apathy and anhedonia."

Journal • CNS Disorders • Psychiatry

Cannabigerol, a minor phytocannabinoid, prevents behavioral changes induced by psychotomimetic drugs. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "Male Swiss mice received intraperitoneal injections of CBG followed by d-amphetamine (AMPH) or MK-801 and were exposed to different behavioral assays, including the open field, novel object recognition (NOR), social interaction, and prepulse inhibition (PPI) tests. These results suggest that CBG therapeutic profile in behavioral assays. Notably, these benefits were observed at reduced concentrations, indicating that this compound represents a promising candidate for future translational and clinical investigations."

Journal • CNS Disorders • Inflammation • Mood Disorders • Pain • Psychiatry • Schizophrenia

Prescribed alternative stimulants among people who use unregulated stimulants: Examining the association between maximum dose reached and medication discontinuation in the first 3 years of implementation in British Columbia, Canada. (PubMed, Addiction) - "Doses of stimulant prescribed alternatives (dextroamphetamine and methylphenidate) that reach 60 mg or more per day appear to be associated with longer treatment episodes than lower doses. Discontinuation is high across both medications. Concurrent opioid agonist treatment appears to be associated with a lower hazard of discontinuation. Dosing alone is unlikely to sustain long-term engagement for all patients."

Journal • Psychiatry • Substance Abuse

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Stephen Robert Marder | Trial completion date: Mar 2026 ➔ Mar 2028 | Trial primary completion date: Mar 2026 ➔ Mar 2028

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Detrimental effects of atomoxetine on visual signal detection in rats: comparison with ADHD psychomotor stimulant drugs. (PubMed, Psychopharmacology (Berl)) - "As well as demonstrating baseline-dependent effects of amphetamine on visual attention, the findings for methylphenidate and atomoxetine suggest important, apparently opposing effects on visual signal detection performance produced via blockade of the DA and NA transporters. The deleterious effects of atomoxetine on performance were especially noteworthy in view of its use as a treatment in ADHD."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Pharmacokinetics at Different Application Sites and Dermal Safety Analysis of Dextroamphetamine Transdermal System (d-ATS) in Healthy Adults and Patients with ADHD. (PubMed, Adv Ther) - "d-ATS's benefits as an additional treatment option for ADHD in children, adolescents, and adults likely outweigh any minor irritation concerns. Transdermal delivery confers practical advantages, and the range of bioequivalent application sites can help minimize dermal irritation. d-ATS's efficacy has been established in prior clinical studies and published elsewhere. Overall, d-ATS represents a valuable, flexible treatment option for children and adolescents with ADHD."

Journal • PK/PD data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pain • Psychiatry

α-Synuclein regulates monoamine transporter capacity and amphetamine-induced efflux via modulation of transporter expression. (PubMed, J Pharmacol Exp Ther) - "This regulatory mechanism has important implications for monoamine homeostasis and for the pharmacological actions of transporter-targeting drugs such as D-amphetamine or 3,4-methylenedioxymethamphetamine ("ecstasy")...This study demonstrates that α-syn enhances the expression and transport capacity of dopamine and serotonin transporters, thereby regulating monoamine clearance and amphetamine-induced efflux. This identifies α-syn as a key modulator of monoaminergic signaling and provides a mechanistic framework linking its normal function to disease-related alterations in neurotransmission."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Stimulant Growth Study: pilot study - adults: Investigation of the effect of a single dose of stimulant medication (dexamphetamine 10mg or methylphenidate 20mg) on appetite and on fasting and postprandial levels of insulin, glucose, leptin and ghrelin in healthy adult volunteers. (ANZCTR) - P=N/A | N=12 | Completed | Sponsor: Chief investigator Dr Alison Poulton | Recruiting ➔ Completed

Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry • LEP

A pilot study to investigate the use of dexamphetamine to treat obesity complicated by diabetes or obstructive sleep apnoea (ANZCTR) - P=N/A | N=24 | Withdrawn | Sponsor: Nepean Hospital | Not yet recruiting ➔ Withdrawn

Trial withdrawal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

Intermediate doses of d-amphetamine promote perseverative risky choices following the presentation of win-paired cues. (PubMed, Behav Pharmacol) - "This effect was particularly evident following losing trials where the win-paired cue was presented. Results are discussed in the context of electronic gambling machine use, and suggestions for research with more commonly used stimulants are offered."

Journal

A Randomised Open-Label Comparison of Dexamphetamine and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD): Symptom Response, Adherence and Weight Impact Over 12 Months. (PubMed, J Paediatr Child Health) - P4 | "Stimulant medications dexamphetamine and methylphenidate appear comparable in short-term symptom response and 12-month persistence after initial randomised allocation, but dexamphetamine may be associated with greater weight loss."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

Presence and Impact of Fatigue in Patients With Multiple Sclerosis. (PubMed, Med Sci Monit) - "Medication exposure (amantadine, modafinil/armodafinil, methylphenidate/dextroamphetamine) was recorded. CONCLUSIONS MS fatigue in veterans is highly prevalent and closely linked to metabolic comorbidities, depression, and sleep disturbance. Common fatigue medications provided no improvement in fatigue severity and quality of life."

Journal • Observational data • Retrospective data • CNS Disorders • Depression • Diabetes • Dyslipidemia • Fatigue • Metabolic Disorders • Multiple Sclerosis • Psychiatry • Sleep Disorder

Analyses of dextroamphetamine and its metabolites in human urine by capillary electrophoresis with diode array and capacitively coupled contactless conductivity detection (CE-DAD-C4D). (PubMed, Anal Bioanal Chem) - "The method was applied to spiked human urine samples using the standard addition technique for endogenous metabolites (hippuric acid and benzoic acid). This study demonstrates the feasibility of clinical and toxicological monitoring involving psychostimulant determination."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research. (PubMed, Pharmacol Rev) - "Only 5 of these putative treatments (aripiprazole, bupropion, d-amphetamine, modafinil, and naltrexone) had also been evaluated in human laboratory and preclinical laboratory contexts. To date, no pharmacotherapies have received US Food and Drug Administration (FDA) approval to treat MUD, and few candidate medications have been systematically evaluated using a translational medications development pipeline (eg, beginning with preclinical research and progressing to human laboratory research and clinical trials). Adhering to the translational pipeline while incorporating new FDA guidance, such as evaluating nonabstinence outcomes, may be useful in facilitating MUD medications development."

Clinical • Journal • Preclinical • Review

Maintained Symptom Control Following a Shortage-Driven Switch to Immediate-Release Dextroamphetamine: A Case Report. (PubMed, Cureus) - "This case report describes a 30-year-old female who was unable to obtain lisdexamfetamine amid the shortage, found mixed amphetamine salts ineffective, but found success with immediate-release dextroamphetamine sulfate, a less frequently used amphetamine. This report serves to demonstrate that immediate-release dextroamphetamine sulfate may be a viable alternative stimulant to address the shortage; however, more research must be conducted to confirm these findings."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A double-blind randomised controlled trial protocol comparing dexamphetamine and placebo effectiveness for obesity management in primary care settings. (PubMed, MethodsX) - "Participants are randomised 1:1 to receive either dexamphetamine or placebo, starting at 5 mg twice daily, with weekly titration up to 30 mg twice daily as tolerated. Dose adjustments are guided by clinical effects and a standardised amphetamine rating scale, with gradual down-titration during the final month. If demonstrated to be effective and safe long-term, dexamphetamine could provide a scalable, practical solution to reduce the individual and societal burden of obesity."

Journal • Genetic Disorders • Obesity

Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men. (PubMed, Fundam Clin Pharmacol) - "Nevertheless, generalizability is limited by the inclusion of healthy men only. Trial Registration: EudraCT: Nr: 2021-005381-17."

Clinical • Journal

Expert meeting report: epidemiology and management of acquired hypothalamic obesity. (PubMed, Front Endocrinol (Lausanne)) - "Pharmacological strategies, including dextroamphetamine and glucagon-like peptide-1 receptor agonists, have demonstrated potential benefits for weight and hyperphagia-related outcomes. Recently, preliminary findings from a prospective, randomized, placebo-controlled clinical trial (TRANSCEND) provided encouraging evidence for the efficacy of setmelanotide, a melanocortin-4 receptor agonist. This perspectives report reviews clinical advances in epidemiology, diagnostics, treatment, and follow-up of patients with aHO and outlines key directions for future research aimed at improving outcomes in this vulnerable population."

Clinical • Journal • Review • Brain Cancer • Cardiovascular • CNS Disorders • CNS Tumor • Endocrine Disorders • Genetic Disorders • Hypothalamic Injury-associated Obesity • Metabolic Disorders • Obesity • Oncology • Vascular Neurology

The use of dexamphetamine for narcolepsy during pregnancy: A case series and literature review. (PubMed, Obstet Med) - "Our findings suggest that therapeutic dexamphetamine use for narcolepsy may not be associated with adverse obstetric or neonatal outcomes. Individualised counselling is essential to balance maternal functional needs against potential pregnancy risks."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Cytomegalovirus Infection • Gynecology • Hypertension • Infectious Disease • Narcolepsy • Obstetrics • Psychiatry • Sleep Disorder

Uveal Effusion and Exudative Macular Detachment Secondary to SSRI and Dexamphetamine Overdose. (PubMed, Retin Cases Brief Rep) - "Overdose of selective serotonin reuptake inhibitors (SSRIs) has been associated with uveal effusion syndrome, and amphetamine-based stimulant use has been implicated in the development of central serous chorioretinopathy (CSCR). In this case, polypharmacy and overdose were associated with unilateral exudative retinal detachment and choroidal effusion, which resolved after discontinuing the offending agents."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Retinal Disorders

Prescription psychostimulants, atomoxetine and the risk of psychosis in adults with history of psychosis: a population-based cohort study. (PubMed, Transl Psychiatry) - "Sensitivity analyses, considering only substance-induced psychotic events, or eight-week intervals and subgroup analyses by sex, age groups and separately for individuals receiving either (dex-)methyphenidate or (lis-)dexamphetamine or atomoxetine or (ar-)modafinil showed consistent results. Contrary to concerns, psychostimulant or atomoxetine treatment was not associated with an increased risk of psychotic events in adults with a history of psychosis. These findings may inform clinicians considering psychostimulant prescriptions in this population."

Journal • CNS Disorders • Psychiatry